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During the past five years, many biopharmaceuticals have found their way into clinical trials and commercial production (1–
4). So far, about 60 million patients 
worldwide have benefited from these 
new drugs. The market for 
biopharmaceuticals was estimated at 
US$33 billion in 2004 and projected to 
reach US$70 billion by the end of the 
decade. During the period 2003–2006, 
regulators in Europe and the United 
States approved 32 biopharmaceuticals 
for human use, including hormones 
and growth factors, therapeutic 
enzymes, vaccines, and monoclonal 
antibody (MAb)-based products. An 
additional 1,600 biopharmaceuticals 
are being evaluated in clinical trials. 
MAbs constitute by far the largest 
product category, with the number of 
such product candidates rising from 75 
to 400 in the period of 2003–2006. The 
global sale of MAbs in 2006 were 
US$20.6 billion (5–8), and currently 25 
are approved for the market. It is 
expected that many new MAbs will be 
approved within the coming years. As 
Figure 1 shows, demand is rapidly 
increasing, making MAb-based products 
the most rapidly growing category of 
biopharmaceuticals (6). 
That increase has been enabled by 
improvements made in the recombinant 
expression technologies that use 
mammalian cells — particularly as 
MAb production went from mouse-
based systems through chimeric to fully 
human antibodies. Mammalian 
expression systems provide a basis for 
producing large quantities of 
biopharmaceutical proteins. These 
systems are gaining market share 
because they are becoming better 
understood and thus offer improved 
performance in yield, speed, and quality 
(Figure 2). However, significant 
improvements are still needed to handle 
the increasing demand for MAbs.
MAMMALIAN CELL LINES
The most used mammalian cell lines for 
biopharmaceutical production are 
Chinese hamster ovary (CHO), 
myeloma, and hybridoma cells. 
Considerable progress has been made in 
optimizing these systems, particularly 
the NS0 myeloma and CHO cell lines. 
Both expression systems are currently 
predominant in biopharmaceutical 
protein production. Fine-tuning of 
vector construction, identification and 
use of selectable markers, optimization 
of transfection in production media, 
gene targeting, and high-throughput 
screening have led to high specific 
productivities ranging 20–60 pg × cell–1 
× day–1 (9–12). That is in most cases 
accomplished by gene amplification, 
which makes cells more prone to 
instability (13–16). Also, lead times for 
clone generation can be shortened to 3–5 
months for certain clones. 
Other mammalian cell lines — e.g., 
human embryonic kidney (HEK) 293, 
baby hamster kidney (BHK), and Cos 
cells — are used to a lesser extent, 
mainly for virus and vaccine production 
(17–19). The “Cell Lines” box details 
those most common. All cell lines used 
for biopharmaceutical protein production 
until now originate from mammals. 
However, certain cell lines have recently 
been derived from duck embryonic stem 
cells for use in vaccine production, 
replacing many old vaccine production 
processes based on embryonated eggs. 
Such nontumorigenic cell lines grow in 
suspension on serum-free media and 
have additional advantages: a lack of 
endogenous retroviruses and no risk of 
cross contamination with human 
adventitious agents (20). They can not 
only be used for expression of therapeutic 
proteins, but also have a significant 
potential for vaccine manufacture. 
Vaccine development using these novel 
cell lines from nonmammalian origin 
will probably replace the egg-based 
manufacturing in the near future.
Most biopharmaceuticals on the 
market are produced in CHO-K1 or 
CHO-derived cell lines such as DHFR–, 
DG44, and DUK-B11 cells. These have 
been used extensively for high-level 
protein production because they enable 
amplification of specific genes through 
selection with an amplifiable marker 
such as dihydrofolate reductase (DHFR) 
or glutamine synthetase (GS). GS can 
act as a dominant selectable marker, 
which can theoretically be used in cells 
that express endogenous GS as well as 
those that do not. A number of proteins 
have been expressed in CHO cells: 
enzymes; recombinant MAbs; blood 
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coagulation factors; and other cell 
surface markers such as chemokines, 
adhesion molecules, growth factors, and 
their receptors (21–24).
Myeloma cell lines — e.g., NS0, 
Sp2/0, and P3X63.Ag8.653 — have 
also been used commonly for high-level 
MAb production. NS0 mouse myeloma 
cells are often favored as a production 
cell line because they contain very low 
levels of endogenous GS compared 
with CHO cells. It is assumed that the 
high productivity of the NS0-GS 
system comes from the fact that the 
cells are derived from immunoglobulin-
producing tumor cells, which have the 
innate machinery for antibody 
production. Another important feature 
of these myeloma cells is their tendency 
to grow well in suspension when 
adapted to serum-free media. Several 
products are already on the market 
using this expression system. It must be 
mentioned, however, that instability as 
well as relatively slow growth have 
been reported (13).
A novel mammalian expression 
system currently under evaluation by 
several biopharmaceutical companies 
uses PER.C6 technology from Crucell 
Holland BV (www.crucell.com) in the 
Netherlands, which is based on a human 
cell line (25, 26). This expression platform 
offers significant advantages over the 
established systems mentioned above. It 
requires no amplification of inserted 
genes to deliver stable clones with high 
levels of protein expression in several 
months. Nor does it require any selection 
agent, as has been used by the DHFR– 
system. A low copy number is sufficient 
to retain stable and efficient protein 
expression. Initial results showed a 
significant potential for MAb and 
recombinant protein production. 
Productivities >2 g/L could be reached 
in fed-batch cultures, 0.9 g × L–1 × day–1 
in continuous perfusion cultures, with 
peak productivities up to 3 g × L–1 × day–
1 without compromising product quality 
(25–27). Because of their human origin, 
PER.C6 cells do not synthesize 
potentially immunogenic MAb glycan 
structures. Productivities of 0.9 g × L–1 × 
day–1 in homogenous continuous 
perfusion systems are considered a 
breakthrough. Corresponding viable cell 
densities are around 100 × 106 cells × 
mL–1, with peak cell densities of  
150 × 106 cells × mL–1 (28). To  
our knowledge, those numbers have 
never been reported before. Such 
achievements suggest a future of small 
and extremely high-producing 
mammalian cell culture systems.
IMPROVEMENTS 
Over the past few years, improvements 
in mammalian expression systems have 
focused on genetic modifications of host 
cells for improving their ability to 
produce more recombinant proteins with 
the proper posttranslational 
modifications (for product quality). 
Many studies have focused on metabolic 
control of cell growth: regulating life 
cycles and limiting apoptotic death. 
Production processes can be 
improved by regulation of proliferation 
after allowing cells to grow rapidly at 
first and achieve a sufficiently high cell 
density for production. That growth 
period is followed by a production 
phase, in which cell density is 
maintained at the same level by 
inhibiting apoptotic cell death. Cyclin-
dependent kinases (CDKs) are good 
targets for such control of proliferation 
because that particular family of protein 
kinases plays a crucial role in processes 
that control cell cycle transitions. Their 
activity is regulated by binding CDKs 
with cyclins to form complexes (after 
phosphorylation) with cyclin-dependent 
inhibitors in the CIP/Kip family, such 
as p21, p27, and p57 (3, 29, 30).
In several studies, p21cip and p27kip 
were overexpressed to cause cell cycle 
arrest at the G1 phase of the cell cycle. 
Productivity of recombinant proteins 
increased as a consequence. Al-Rubeai et 
al. showed a fourfold increase in 
productivity by p21cip overexpression 
resulting from a lengthening of the cell 
cycle, which increased mitochondrial 
mass and activity and improved 
ribosome biogenesis (31).
Programmed cell death (apoptosis) 
occurs in essentially all industrially 
MENTIONED CELL LINES
CHO: an epithelial cell line derived from 
the ovaries of Chinese hamsters 
(Cricetulus griseus)
DHFR–: a CHO cell line based on CHO 
duk cells (dhfr refers to dihydrofolate 
reductase); for example, see ATCC* 
catalog number CRL-9096
DG44: a CHO cell line 
DUK-B11: a CHO cell line
NS0: a myeloma cell line derived from B 
lymphocytes of mice (Mus musculus); for 
examples, see ATCC* catalog numbers 
CRL-1827, -2695, and -2696
HEK293: an epithelial cell line derived 
from human embryonic kidney cells 
transformed with adenovirus 5 DNA; for 
example, see ATCC* catalog number 
CRL-1573
BHK: a cell line derived from the kidney 
cells of baby Syrian golden hamsters 
(Mesocricetus auratus); for example, see 
ATCC* catalog number CRL-1632
COS-1, COS-7: fibroblast cell lines 
derived from the kidney cells (SV40 
transformed) of African green monkeys 
(Cercopithecus aethiops); for examples, 
see ATCC* catalog numbers CRL-1650 
and -1651 
Sp2/0: a lymphoblast myeloma cell line 
derived from B lymphocyte hybridomas 
of mice (Mus musculus); for example, see 
ATCC* catalog number CRL-2016
P3X63.Ag8.653: a lymphoblast 
myeloma cell line derived from B 
lymphocytes hybridomas of mice (Mus 
musculus) and rats (Rattus norvegicus)
PER.C6: a trademarked cell line (derived 
from a human retinal cell) developed 
and owned by Crucell Holland BV
*www.atcc.org/SearchCatalogs/CellBiology.cfm
Figure 1: The amount of MAbs produced is 
projected to more than double.
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Figure 2: Number of products made using 
mammalian, microbial, and yeast expression 
systems
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available cell lines: e.g., CHO, 
myelomas, hybridomas, and HEK293 
cells. Apoptosis is an obstacle to these 
cells surviving high cell densities. 
Therefore its prevention should at least 
contribute to maximizing productivity of 
mammalian cells in bioreactors. One of 
the most investigated pathways involves 
the Bcl-2 family of proteins. It has both 
antiapoptotic and proapoptotic members, 
many of which are associated with 
mitochondria. Antiapoptotic proteins 
include Bcl-2 and Bcl-xl, which are 
localized in the mitochondrial 
membrane, where they prevent release of 
cyt c, a cytotoxic protein. A member of 
the proapoptotic subfamily is Bax, which 
is also involved in the pathway associated 
with cyt c release. Several studies have 
shown that overexpression of Bcl-2 
delayed apoptosis during cell culture, 
consequently improving productivity. 
Other studies, however, showed only a 
delay in apoptosis but no productivity 
increase (32–37). It can thus be concluded 
that inhibiting apoptosis — whether 
through the Bcl-2 method or simply by 
limiting cell culture nutrients — will 
enhance cellular viability but will not 
necessarily increase productivity.
Other methods of increasing titers 
focus on increasing transgene expression 
levels. Recent improvements include 
incorporation into transgene constructs 
of DNA elements that can either act as 
enhancers or prevent transgene silencing 
once it has been integrated into a 
genome. Examples include STAR 
technology (stimulating and 
antirepressor elements) from Crucell and 
other types of chromatin-opening 
elements, DNA elements used to prevent 
expression silencing by integration of the 
constructs into heterochromatin. That 
could improve stability — and possibly 
productivity — while reducing the 
number of clones to be screened (38–40). 
The use of artificial chromosomes (e.g., 
the ACE system from Chromos 
Molecular Systems Inc., www.chromos.
com, of Canada) that function as stable, 
nonintegrating vectors with large 
carrying capacity, allowing multiple 
copies of the same transgene, have 
resulted in a fourfold higher expression 
level over CHO-dhfr expression (41). 
Transgene expression can also be 
increased by enhancing transgene 
promoter strength using engineered 
zinc-finger protein transcription factors 
that bind a DNA sequence within a 
promoter (42).
Targeted knockout of mammalian 
host-cell genes is now possible using 
RNA interference or engineered zinc 
fingers (43, 44). Using such an approach, 
an increase in antibody potency — rather 
than yield — was obtained by modifying 
the glycosylation machinery using RNA 
interference targeting a 
fucosyltransferase. MAbs produced by 
such cells have a reduced fucosylation, 
with a concomitant increase in a 
particular effector function that is often 
important for clinical efficacy: antibody-
dependent cellular cytotoxicity (45). 
CHOICE OF EXPRESSION SYSTEM
Process development for 
biopharmaceuticals is dictated by several 
key success factors: product quality and 
safety, speed of generating clinical phase 
1–3 material, economy of manufacturing 
processes for marketed products, and 
regulatory acceptance. Not surprisingly, 
those factors also play a key role in 
evaluating mammalian cell expression 
systems for use in production of 
pharmacologically active glycoproteins. 
To date, the most likely candidates for 
efficient expression of glycoproteins are 
mammalian cell lines, especially CHO 
and mouse myeloma cells. 
So the most important factors to take 
into consideration when choosing an 
optimal expression system, are 
productivity, process economics, product 
quality and safety, lead times, scalability, 
and regulatory acceptance.
Productivity: For glycoproteins, 
expression levels are mainly determined 
by the promoter construct, its copy 
number and site of integration into the 
chromosome, and the type of protein in 
question. Volumetric productivity (VP) 
is determined by the specific productivity 
and growth performance of cells. It will 
ultimately determine the total yield of an 
expression system/process. Both specific 
productivity and maximum cell density 
directly affect the required culture 
volume and production scale for a given 
amount of MAbs. 
Table 1 provides an example in 
which VP is mainly determined by the 
maximum cell density reached in a 
continuous, steady-state perfusion 
culture. Intrinsic productivity is  
15 pg × cell–1 × day–1 and, in one case, 
the maximum cell density is 10 ×  
106 cells × ml–1. In the other case, 100 
× 106 cells × mL–1 is reached using the 
PER.C6 human cell line. As a result, 
VP is tenfold higher in the high–cell-
density culture. A required amount of 
10 kg purified protein can be produced 
in 11 runs at the 500-L scale using the 
lower-density cultures — compared 
with only one run in a high-
productivity culture. In addition, a 
tenfold smaller amount of cell culture 
medium is required. 
Figure 3 shows the same relationship 
in achieving 10 kg of product. Again, at 
lower VPs, more runs are needed to 
DSM AND CRUCELL ANNOUNCE PER.C6 MILESTONE
On 11 March 2008, DSM Biologics of Parsippany, NJ (www.dsmpharmaceuticals.com) 
and Dutch biotechnology company Crucell Holland BV (www.crucell.com) announced 
that another important milestone has been achieved with the PER.C6 technology 
platform for production of monoclonal antibodies and other recombinant proteins. 
Scientists working at the Percivia Development Center (www.percivia.com) reached a 
record level titer of 15 g/L at harvest for an antibody product. The development 
center is a joint venture between DSM and Crucell located in Cambridge, MA.
Percivia CEO Marco Cacciuttolo said, “This high titer achievement — the highest 
reported to date — marks a major event for the biopharmaceutical industry. It 
demonstrates the power and robustness of the PER.C6 manufacturing platform, and it 
clearly shows that this manufacturing platform will have a major impact on the overall 
economics of manufacturing biopharmaceuticals. DSM and Crucell recognized the 
enormous potential of this technology when starting the Percivia joint venture just 
over a year ago. These breakthrough results achieved in a single year reinforce the 
special properties and abilities of this manufacturing platform. Based on our scientific 
data today, we are confident that we will be able to drive productivity even further.”
Crucell’s vice president of business development Martina Molsbergen added “The  
PER.C6 platform can reduce the risk of supply limitations and potentially postpone 
major capital expenditure decision hurdles for drug development companies.”
obtain the same amount of product. The 
examples show that improving specific 
productivities in combination with high 
cell densities will significantly affect 
process economics: costs of goods and 
use of plant capacity. Recent data show 
current MAb productivities at the level 
of multiple grams per liter have been 
achieved in CHO, NS0, and PER.C6 
cell lines (28). 
Product quality is predominantly 
determined by posttranslational 
modifications, including glycosylation 
and protein folding, which will largely 
determine a molecule’s biological 
activity. Differences among the 
mammalian expression systems are well 
documented, particularly for CHO and 
NS0 cells (46). Despite those differences, 
most approved MAbs are produced in 
one or the other system. 
Glycosylation patterns and protein 
structures are influenced by host-cell 
enzymatic systems as well as bioreactor 
conditions (24, 47). Therefore, selection 
of host cells and culture conditions must 
take into account the requirement for 
stably producing each specific 
glycosylation pattern. So appropriate 
analytical tools must be used for in-
process monitoring to determine early in 
a cell culture process, whether changes 
due to culture conditions might occur. 
Several protein analytical tools are 
available for assessment of glycovariants: 
peptide mapping, isoelectric focusing, 
oligosaccharide mapping, matrix-
assisted laser desorption ionization time 
of flight (MALDI-TOF) mass 
spectrometry, capillary electrophoresis, 
and specific potency assays. 
WORKS IN PROGRESS
Several mammalian expression 
platforms have been investigated during 
the past decade. Most MAb products 
are produced using CHO- and NS0-
based systems. Novel technologies are 
being explored, from improving DNA 
vector constructs to optimizing existing 
cell lines as well as novel platforms. 
Such technologies hold great promise. 
For example, the PER.C6 human cell 
line has already outperformed 
established systems and brought new 
insights in mammalian cell technology 
(see the “Milestone” box).
In addition to yield improvements, 
efforts are being made to enhance 
cellular properties that enable more 
efficient and effective process 
performance. One continuing goal is for 
smaller scale processes to better predict 
large-scale performance in industrial 
settings. Improvements discussed here 
should lead to cost-effective production 
of biopharmaceutical proteins for 
treatment of life threatening diseases. 
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Figure 3: The lower the productivity, the 
more fermentation runs are required.
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Table 1: Comparing high- and low-producing 
cell lines for production of 10 kG of recombinant 
proteins in a continuous perfusion culture
CHO PER.C6
Productivity  
(pg/cell/day)
15 15
Maximum cell density 
(×106 per mL)
10 100
Protein (mg/L) 150 1500
Downstream yield 0.5 0.5
Required protein (g) 10,000 10,000
Crude amount of 
required protein (g)
20,000 20,000
Culture volume (L) 133,333 13,333
Number of 50-L runs 107 9
Number of 100-L runs 53 4
Number of 250-L runs 21 2
Number of 500-L runs 11 1
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